They didn’t announce that B for IBD is dead or failed: 1) they have a nice license ongoing with Alfasigma for ibd. 2) in the 10k they announced a b for uc trial still in the works but through language also announced that they are friggin clueless in developing the oral pill and it will take more time.
IBD is alive and well but the ongoing theme with ipix is: same ole slow n sloppy bs just a year later. They wreak of human incompetence across all levels.
Now, if Covid topline is great: $2-5 per share is totally possible, but the data needs to be truly great.
A dollar on good dayta would still make pappy happy…
News 
Market Data 
Discover 
